REST EZ, Inc. Files 2024 Annual Report

TL;DR

REST EZ filed its 2024 10-K. Check financials for pharma prep biz.

AI Summary

REST EZ, Inc. filed its annual report on Form 10-K for the fiscal year ended March 31, 2024. The company, incorporated in Wyoming and headquartered in Riverton, UT, operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 1398 West Mason Hollow Drive, Riverton, UT 84065, with a business phone number of 801-300-2542.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of REST EZ, Inc.'s financial performance and business operations for the fiscal year 2024.

Risk Assessment

Risk Level: low — The provided text is a standard 10-K filing header and does not contain specific financial or operational details that would indicate a high-risk level.

Key Players & Entities

• REST EZ, Inc. (company) — Registrant
• March 31, 2024 (date) — Fiscal year end
• Wyoming (jurisdiction) — State of incorporation
• 82-4268982 (identifier) — IRS Number
• 1398 W. Mason Hollow Dr. Riverton, UT 84065 (address) — Principal Executive Offices
• 801-300-2542 (phone_number) — Issuer's Telephone Number
• 2834 (sic_code) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

Key Financial Figures

• $2,000 — he Company or more and draw a salary of $2,000 per month. 6 Table of Contents Item
• $36,805 — 24, we had a working capital deficit of $36,805. The Company believes it does not have
• $100,000 — icated he would be able to fund another $100,000 if the company needs further assistance
• $519,443 — t for orders in the aggregate amount of $519,443; the proceeds from these orders is used
• $0.010 — quotation system, the offering price of $0.010 per share for the shares of common stoc
• $0.001 — 0,000 shares of common stock, par value $0.001 per share. We may also issue additiona

Filing Documents

• restez20240331_10k.htm (10-K) — 564KB
• ex_770095.htm (EX-31.1) — 10KB
• ex_770096.htm (EX-31.2) — 10KB
• ex_770097.htm (EX-32.1) — 6KB
• ex_770098.htm (EX-32.2) — 5KB
• logo2.jpg (GRAPHIC) — 24KB
• restez20240331_10kimg001.jpg (GRAPHIC) — 6KB
• 0001185185-25-000130.txt ( ) — 2438KB
• rest-20240331.xsd (EX-101.SCH) — 18KB
• rest-20240331_cal.xml (EX-101.CAL) — 19KB
• rest-20240331_def.xml (EX-101.DEF) — 76KB
• rest-20240331_lab.xml (EX-101.LAB) — 143KB
• rest-20240331_pre.xml (EX-101.PRE) — 88KB
• restez20240331_10k_htm.xml (XML) — 127KB

Risk Factors

Risk Factors 7 Item 1B Unresolved Staff Comments 10 Item 2

Properties

Properties 10 Item 3

Legal Proceedings

Legal Proceedings 10 Item 4 Mine Safety Disclosures 10 PART II Item 5 Market for Common Equity and Related Stockholder Matters 11 Item 6

Selected Financial Data

Selected Financial Data 11 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 15 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 16 Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 30 Item 9A

Controls and Procedures

Controls and Procedures 30 Item 9B Other Information 31 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 31 PART III Item 10 Directors, Executive Officers, and Corporate Governance 32 Item 11

Executive Compensation

Executive Compensation 33 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 33 Item 13 Certain Relationships and Related Transactions, and Director Independence 34 Item 14 Principal Accountant Fees and Services 34 PART IV Item 15 Exhibits and Financial Statement Schedules 35 Item 16 Form 10-K Summary 35

Signatures

Signatures 36 PART I

Description of Business

Item 1. Description of Business. The Company was incorporated in the State of Wyoming on October 17, 2016. Rest EZ, Inc. markets a sleeping aid soft gel capsule to be sold to the general public through wholesalers and retailers, as well as online at www.RestEz.net. The Rest EZ Sleep Aid Supplement soft gel capsule is a liquid gel capsule containing soybean oil, Melatonin, gelatin, glycerin, L-glutamic Acid, yellow beeswax, purified water, L-leucine, L-arginine and lecithin. It provides faster rate with up to 100% absorption by the body. The gels are manufactured by an unaffiliated outside provider, Sport Energy. Beyond the general FDA requirement that every dietary supplement be labeled as such, either with the term "dietary supplement" or with a term that substitutes a description of the product's dietary ingredient(s) for the word "dietary" (e.g., "herbal supplement" or "calcium supplement"), and the FDA's safety monitoring responsibilities for dietary supplement firms once a dietary supplement is on the market, there are no additional FDA requirements specific to this product, and federal law does not require dietary supplements to be proven safe to FDA's satisfaction before they are marketed. Rest EZ, Inc. has commenced its full operations of having its Rest EZ Sleep Aid Supplement soft gel distributed nationwide through wholesalers and retailers, as well as online at www.RestEz.net. The Company does not manufacture its own soft gel capsule; this is outsourced to Sport Energy, an unaffiliated outside provider, who manufactures liquid gels. We plan during the next twelve months to increase our client base by aggressively marketing our product to generate: (1) wholesalers and expand our wholesale base; (2) sales on our website; and (3) sales through retail chain stores and word of mouth advertising. Rest EZ Inc. Inc. has developed a plan to market its soft gel capsule to the general public. Rest EZ, Inc. has wholesale distribution, retail, and online sales th

Risk Factors

Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the following risks, as well as general economic and business risks, and all of the other information contained in this Report. Any of the following risks could harm our business, operating results and financial condition and cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. When determining whether to invest, you should also refer to the other information contained in this Report including our financial statements and the related notes thereto. (A) RISKS RELATED TO OUR BUSINESS Risks Related to Our Business If the Company needs additional money and if money is raised through the sale of our securities, the issuance of those securities could result in dilution to our existing security holders. If we raise money through debt financing or bank loans, we may be required to secure the financing with some or all of our business assets. Side effects of the product. -When taken by mouth in high doses, any sleeping aid is possibly unsafe. There is some concern that it could harm kidney, liver, or heart function. However, a connection between high doses and these negative effects has not been proven. -Sleep Aid can also cause stomach pain, nausea, diarrhea, and muscle cramping if more than the recommended amount is taken. -There is some concern that combining sleeping aids with caffeine and the herb ephedra (also called Ma Huang) might increase the chance of having serious side effects such as nausea, or stomach pain. -There is concern that sleeping aids might cause irregular heartbeat in some people, but more information is needed to know if Sleep Aids can cause this problem. It is not known how the aforementioned side effects could impact our business. We suspect some potential users of the product may decide to forego purchase of the produ

View Full Filing

View this 10-K filing on SEC EDGAR